Phentermine

Phentermine

SCHEMBL41585

CC(C)(N)Cc1ccccc1.Cl

nearest known ligand 0.95

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

SLC6A2

The experimentally established mechanism targets of Phentermine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 known ✓ P23975 2/20 0.95
TAAR1 Q96RJ0 1/20 0.95
HTR2A P28223 1/20 0.58
SLC6A4 P31645 1/20 0.58
HRH1 P35367 1/20 0.58
HTR2B P41595 1/20 0.58
CHRNA4 P43681 1/20 0.58
SLC6A3 Q01959 1/20 0.58
CYP2D6 P10635 2/20 0.52
LMNA P02545 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.50
HIF1A Q16665 1/20 0.50
TRPA1 O75762 1/20 0.45
MAOB P27338 3/20 0.44
MAOA P21397 2/20 0.44
MAPK1 P28482 1/20 0.43
CYP1A2 P05177 2/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
CYP3A4 P08684 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phentermine SCHEMBL25214698 0.98 SLC6A2 (0.91) SLC6A2TAAR1HTR2ASLC6A4HRH1
Phentermine SCHEMBL26615 0.97 SLC6A2 (1.00) SLC6A2TAAR1HTR2ASLC6A4HRH1
Phentermine SCHEMBL10392295 0.97 SLC6A2 (1.00) SLC6A2TAAR1HTR2ASLC6A4HRH1
Phentermine SCHEMBL28695767 0.95 SLC6A2 (0.95) SLC6A2TAAR1HTR2ASLC6A4HRH1
Phentermine SCHEMBL28729624 0.95 SLC6A2 (0.95) SLC6A2TAAR1HTR2ASLC6A4HRH1
Phentermine SCHEMBL3676484 0.95 SLC6A2 (0.95) SLC6A2TAAR1HTR2ASLC6A4HRH1
Phentermine SCHEMBL677133 0.93 SLC6A2 (0.91) SLC6A2TAAR1HTR2ASLC6A4HRH1
Phentermine SCHEMBL29261099 0.93 SLC6A2 (0.91) SLC6A2TAAR1HTR2ASLC6A4HRH1
SCHEMBL11709671 0.89 SLC6A2 (0.83) SLC6A2TAAR1HTR2ASLC6A4HRH1
Phentermine SCHEMBL8142147 0.87 SLC6A2 (0.79) SLC6A2TAAR1HTR2ASLC6A4HRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 3604 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122060114-A Temporary plugging material for shale gas steering fracturing, preparation method and temporary plugging agent 中国石油集团渤海钻探工程有限公司 2026-05-19 CN claimed
US-20260131089-A1 DRUG DELIVERY DEVICES AND METHODS FOR ADMINISTERING SUBSTANCES TO A BODY CAVITY BY HETEROGENOUS AEROSOLIZATION FOR TREATMENT OF BINGE-EATING DISORDERS AND/OR OBESITY APTARGROUP, INC. (US) 2026-05-14 US claimed
US-12491325-B2 Drug delivery devices and methods for administering substances to a body cavity by heterogenous aerosolization for treatment of binge-eating disorders and/or obesity APTARGROUP, INC. (US) 2025-12-09 US claimed
EP-4654966-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF OBESITY AND DISEASES ASSOCIATED WITH FAT CELL ENLARGEMENT MELLICELL, INC. (US) 2025-12-03 EP claimed
WO-2025137653-A1 METHODS AND COMPOSITIONS OF POLYCYCLIC AND A DUAL ACTING NITROXIDE COMPOUNDS FOR TREATMENT OF FAT CELL ASSOCIATED DISEASES MELLICELL, INC. (US) 2025-06-26 WO claimed
US-20250205222-A1 ANTIOBESITY COMPOSITIONS JACKSON MILTON S (US) 2025-06-26 US claimed
US-12303514-B2 Immediate and controlled release appetite suppressant compositions for weight loss Red Mountain Med Spa, LLC (US) 2025-05-20 US claimed
EP-3793518-B1 AN ORAL TABLET FOR TASTE MASKING OF ACTIVE INGREDIENTS COMPRISING NON-DIRECTLY COMPRESSIBLE SUGAR ALCOHOL PARTICLES FERTIN PHARMA AS (DK) 2025-03-26 EP claimed
CN-119569945-A Five-membered random copolymer, preparation method thereof, filtrate reducer and water-based drilling fluid 中国石油天然气集团有限公司 2025-03-07 CN claimed
EP-4493172-A1 ANTIOBESITY COMPOSITIONS Jackson, Milton S. (US) 2025-01-22 EP claimed
EP-0652774-B1 PHARMACEUTICAL COMPOSITION FOR TOPICAL USE CONTAINING A CROSSLINKED CATIONIC POLYMER AND AN ALKOXYLATED ETHER PROCTER & GAMBLE (US) 1997-05-07 EP claimed
US-5614178-A TRANSDERMAL THE PROCTER & GAMBLE COMPANY (US) 1997-03-25 US claimed
US-5527788-A Method and composition for treating obesity comprising dehydroepiandrosterone (DHEA), or a derivative thereof, and an anorectic agent LOUISIANA STATE UNIV. MEDICAL CENTER FOUNDATION (US) 1996-06-18 US claimed
EP-0652774-A1 PHARMACEUTICAL COMPOSITION FOR TOPICAL USE CONTAINING A CROSSLINKED CATIONIC POLYMER AND AN ALKOXYLATED ETHER. PROCTER & GAMBLE (US) 1995-05-17 EP claimed
CN-1091317-A Improve the part input of medicine PROCTER & GAMBLE (US) 1994-08-31 CN claimed
EP-0608320-A1 ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS RICHARDSON-VICKS, INC. (US) 1994-08-03 EP claimed
EP-0608322-A1 ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS RICHARDSON-VICKS, INC. (US) 1994-08-03 EP claimed
WO-1994002176-A1 PHARMACEUTICAL COMPOSITION FOR TOPICAL USE CONTAINING A CROSSLINKED CATIONIC POLYMER AND AN ALKOXYLATED ETHER THE PROCTER & GAMBLE COMPANY (US) 1994-02-03 WO claimed
WO-1993007902-A1 ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS RICHARDSON-VICKS, INC. (US) 1993-04-29 WO claimed
WO-1993007903-A1 ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS RICHARDSON-VICKS, INC. (US) 1993-04-29 WO claimed